title: Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects.
abstract: Trecovirsen, a 25-mer antisense phosphorothioate oligonucleotide targeted at the gag site of the HIV gene, was administered to HIV-positive volunteers as an i.v. infusion. Single doses ranged from 0.1 to 2.5 mg/kg in an ascending escalation in cohorts of 6 to 12 subjects. Plasma trecovirsen concentrations and pharmacokinetic parameters could be assessed at doses > or = 0.3 mg/kg. Peak plasma concentrations and AUC values increased disproportionately with increasing dose while elimination half-life increased and plasma clearance decreased, indicating a saturable process over this dose range. The only significant adverse event observed was an isolated, transitory increase in activated partial thromboplastin time at doses > or = 2.0 mg/kg that was related to plasma trecovirsen concentrations and is attributed to the polyanionic character of the molecule. Thus, trecovirsen administration was well tolerated in single i.v. doses up to 2.5 mg/kg.
authors.affiliation: Service de Médecine Interne, Hôpital Cochin, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Séréni
authors.forename: R
authors.initials: R
authors.lastname: Tubiana
authors.forename: C
authors.initials: C
authors.lastname: Lascoux
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: O
authors.initials: O
authors.lastname: Taulera
authors.forename: A
authors.initials: A
authors.lastname: Bourque
authors.forename: A
authors.initials: A
authors.lastname: Cohen
authors.forename: B
authors.initials: B
authors.lastname: Dvorchik
authors.forename: R R
authors.initials: RR
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Tournerie
authors.forename: A
authors.initials: A
authors.lastname: Gouyette
authors.forename: P J
authors.initials: PJ
authors.lastname: Schechter
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D020319:Oligodeoxyribonucleotides, Antisense / Q000009:adverse effects / Q000493:pharmacokinetics*; D010314:Partial Thromboplastin Time; D013873:Thionucleotides / Q000009:adverse effects / Q000493:pharmacokinetics*